Pulmonary vaccine delivery

References

• Woodland DL, Randall TD. Anatomical features of anti-viral immunity in the respiratory tract. Sem. Immunol.16, 163–170 (2004).
   PubMedGoogle Scholar
• Brandtzaeg P. Humoral immune-response patterns of human mucosae – induction and relation to bacterial respiratory tract infections. J. Infect. Dis.165, S167–S176 (1992).
   PubMed Web of Science ®Google Scholar
• Breiman RF, Butler JC, McInnes PM. Vaccines to prevent respiratory infection: opportunities on the near and far horizon. Curr. Opin. Infect. Dis.12, 145–152 (1999).
   PubMed Web of Science ®Google Scholar
• Mestecky J. Mucosal Immunology (3rd Edition). Academic Press, CA, USA (2005).
   Google Scholar
• MacDonald TT. The mucosal immune system. Parasite Immunol.25, 235–246 (2003).
   PubMed Web of Science ®Google Scholar
• Lugton I. Mucosa-assocaited lymphoid tissues as sites for uptake, carriage and excretion of tubercle bacilli and other pathogenic mycobacteria. Immunol. Cell Biol.77, 364–372 (1999).
   PubMed Web of Science ®Google Scholar
• Kiyono H, Kweon MN, Hiroi T et al. The mucosal immune system: from specialized immune defense to inflammation and allergy. Acta Odontol. Scand.59(3), 145–153 (2001).
   PubMed Web of Science ®Google Scholar
• van Ginkel FW, Nguyen HH, McGhee JR. Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg. Infect. Dis6(2), 123–132 (2000).
   PubMed Web of Science ®Google Scholar
• Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J. Exp. Med.184, 1879–1890 (1996).
   PubMed Web of Science ®Google Scholar
• Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J. Clin. Immunol.7, 265–276 (1987).
   PubMed Web of Science ®Google Scholar
• Mackay CR. Homing of naive, memory and effector lymphocytes. Curr. Opin. Immunol.5, 423–427 (1993).
   PubMed Web of Science ®Google Scholar
• McCray PBJ, Bentley L. Human airway epithelia express a β-defensin. Am. J. Respir. Cell Mol. Biol.16, 343–349 (1997).
   PubMed Web of Science ®Google Scholar
• Larrick JW, Hirata M, Balint RF et al. Human CAP18: a novel antimirobial liposaccharide-binding protein. Infect. Immun.63, 1291–1297 (1995).
   PubMed Web of Science ®Google Scholar
• Wright JR. Immunomodulatory functions of surfactant. Physiol. Rev.77, 931–962 (1997).
   PubMed Web of Science ®Google Scholar
• Bivas-Benita M, Ottenhoff THM, Junginger HE et al. Pulmonary DNA vaccination: concepts, possibilities and perspectives. J. Control. Release107, 1–29 (2005).
   PubMed Web of Science ®Google Scholar
• Bezdicek P, Crystal RG. Pulmonary macrophages. In: The Lung: Scientific Foundations. Crystal RG, West JB (Eds). Lippincott-Raven Publishers, PA, USA 859–875 (1997).
   Google Scholar
• Holt PG, Stumbles PA, McWilliam AS. Functional studies on dendritic cells in the respiratory tract and related mucosal tissues. J. Leukoc. Biol.66, 272–275 (1999).
   PubMed Web of Science ®Google Scholar
• Poulter LW. Pulmonary macrophages. In: Pulmonary Defences. Stockley RA (Ed.). John Wiley & Sons Ltd, Chichester, UK 77–92 (1997).
   Google Scholar
• Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu. Rev. Immunol.18, 767–811 (2000).
   PubMed Web of Science ®Google Scholar
• Bienenstock J, McDermott MR. Bronchus- and nasal-associated lymphoid tissues. Immunol. Rev.206, 22–31 (2005).
   PubMed Web of Science ®Google Scholar
• Moyron-Quiroz JE, Rangel-Moreno J, Kusser K et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat. Med.10, 927–934 (2004).
   PubMed Web of Science ®Google Scholar
• Smith DJ, Bot S, Dellamary L et al. Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine21, 2805–2812 (2003).
   PubMed Web of Science ®Google Scholar
• Hitchner SB, Reising G. Flock vacciantion for Newcastle disease by atomization of the B1 strain of virus. Proc. Am. Vet. Med. Assoc.89, 258–264 (1952).
   Google Scholar
• Murphy D, van Alstine WG, Clark LK et al. Aerosol vaccination of pigs against Mycoplasma hyopneumoniae infection. Am. J. Vet. Res.54, 1874–1880 (1993).
   PubMedGoogle Scholar
• Sharma JM. Introduction to poultry vaccines and immunity. Adv. Vet. Med.41, 481–494 (1999).
   PubMedGoogle Scholar
• al-Tarcga B, Kojnok J, Varro C. Immunization of day-old chicks having maternally derived antibodies against infectious bronchitis: degree of protection as monitored by cilliary activity after intratracheal challenge. Acta Vet. Hung.39, 83–93 (1991).
   PubMedGoogle Scholar
• Deuter A, Douthee DJ, Mockett APA. Folwpox virus: pathogenicity and vaccination of day-old chickens via the aerosol route. Res. Vet. Sci.50, 362–364 (1991).
   PubMed Web of Science ®Google Scholar
• Aleksandrov NI, Gefen NY. A method of aerogenic (inhalation) immunization and possibilities of improving it. Voenno-Med. Zhur.11 (1958).
   Google Scholar
• Eigelsbach HT, Tigertt WD, Saslaw S et al. Live and killed tularemia vaccines: evaluation in animals and man. Proc. Army Sci. Conf. US Military Acad., West Point, NY1, 235–246 (1962).
   Google Scholar
• Aleksandrov NI, Gefen NE, Garin NS et al. Experiment of mass aerogenic vacciantion of people against anthrax. Voenno-Med. Zhur.8, 27–32 (1959).
   PubMedGoogle Scholar
• Rosenthal SR, McEnery JT, Raisys N. Aerogenic BCG vaccination against tuberculosis in animal and human subjects. J. Asthma Res.5(4), 309–323 (1968).
   PubMedGoogle Scholar
• Ganguly R, Ogra PL, Regas S et al. Rubella immunization of volunteers via the respiratory tract. Infect. Immun.8(4), 497–502 (1973).
   PubMedGoogle Scholar
• Shlyakhov EN. Allergy in anthrax. Kartia Moldoveniaska, Kishinev188 (1968).
   Google Scholar
• Shlyakhov EN, Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine12, 727–730 (1994).
   PubMed Web of Science ®Google Scholar
• Shlyakhov E, Rubinstein E, Novikov I. Anthrax post-vaccinal cell-mediated immunity in humans: kinetics pattern. Vaccine15(6–7), 631–636 (1997).
   PubMedGoogle Scholar
• Tarnvik A. Nature of protective immunity to Francisella tularensis. Rev. Infect. Dis.11, 440–451 (1989).
   PubMedGoogle Scholar
• Hornick RB, Eigelsbach HT. Aerogenic immunization of man with live tularemia vaccine. Bacteriol. Rev.30(3), 532–538 (1966).
   PubMedGoogle Scholar
• Cutts FT, Clements CJ, Bennett JV. Alternative routes of measles immunization. Biologicals25, 323–328 (1997).
   PubMed Web of Science ®Google Scholar
• Bennett JV, Fernadez de Castro J, Valdespino-Gomez JL et al. Aerosolized measles and measles–rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trial in Mexican school children. Bull. World Health Organ.80, 806–812 (2002).
   PubMed Web of Science ®Google Scholar
• Wong-Chew RM, Islas-Romero R, Garcia-Garcia MDL et al. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine24(5), 683–690 (2005).
   PubMedGoogle Scholar
• Coates AL, Tipples G, Leung K et al. How many infective viral particles are necessary for successful mass measles immunization by aerosol? Vaccine24, 1578–1585 (2006).
   PubMed Web of Science ®Google Scholar
• Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination. Res. Care50(9), 1161–1176 (2005).
   PubMedGoogle Scholar
• LiCalsi C, Maniaci M, Christensen T et al. A powder formulation of measles vaccine for aerosol delivery. Vaccine19, 2629–2636 (2001).
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Auguado MT. Measles aerosol immunization and its potential contribution to further reduce measles mortality worldwide. In: Respiratory Drug Delivery. Dalby RN, Bryon PR, Peart J et al. (Eds). Davis Healthcare International Publishing, IL, USA 65–72 (2006).
   Google Scholar
• Sepulveda-Amor JS, Valdespino-Gomez JL, Garcia-Garcia MDL et al. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccine in school age children. Vaccine20, 2790–2795 (2002).
   PubMed Web of Science ®Google Scholar
• Lombry C, Marteleur A, Arras M et al. Local and systemic immune responses to intratracheal instillation of antigen and DNA vaccines in mice. Pharm. Res.21, 127–135 (2004).
   PubMed Web of Science ®Google Scholar
• Bivas-Benita M, van Meijgaarden KE, Franken KL et al. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T cell spitopes of Mycobacterium tuberculosis. Vaccine22, 1609–1615 (2004).
   PubMed Web of Science ®Google Scholar
• Gupta PK, Hickey AJ. Contemporary approaches in aerosolized drug delivery to the lung. J. Control. Release17, 129–148 (1991).
   Web of Science ®Google Scholar
• Reynolds HY. Modulating airway defenses against microbes. Curr. Opin. Pulmonary Med.8(3), 154–165 (2002).
   PubMed Web of Science ®Google Scholar
• Leung K, Louca E, Coates AL. Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency. Chest126, 1619–1627 (2004).
   PubMed Web of Science ®Google Scholar
• Denyer J, Dyche T, Nikander K et al. Halolite: a novel liquid drug aerosol delivery system. Thorax52(Suppl. 6), A83 (1997).
   Google Scholar
• Ganderton D. Targeted delivery of inhaled drugs: current challenges and future goals. J. Aerosol. Med.12(Suppl. 1), S3–S8 (1999).
   Google Scholar
• Dolovich M. New propellant-free technologies under investigation. J. Aerosol. Med.12(Suppl. 1), S9–S17 (1999).
   Google Scholar
• Colan JW, Shen H, Kuolee R et al. Aerosol, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an α-β T cell- and interferon γ-dependent mechanism. Vaccine23, 2477–2485 (2005).
   PubMedGoogle Scholar
• Cohn ML, Davis CL. Airborne immunization against tuberculosis. Science128, 1282–1283 (1958).
   PubMed Web of Science ®Google Scholar
• Lefford MJ. Induction and expression of immunity after BCG immunization. Infect. Immun.18(3), 646–653 (1977).
   PubMed Web of Science ®Google Scholar
• Schwarz LA, Johnson JL, Black M et al. Delivery of DNA-cationic liposome complexes by small-particle aerosol. Hum. Gene Ther.7, 731–741 (1996).
   PubMed Web of Science ®Google Scholar
• Newman SP, Weisz AWB, Talaee N et al. Improvement of drug delivery with breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax46, 712–716 (1991).
   PubMed Web of Science ®Google Scholar
• Brown AR, George DW, Matteson DK. Vaccinator device for delivering propellant-driven aerosols of Streptococcus suis bacterin into the respiratory tracts of swine. Vaccine15(11), 1165–1173 (1997).
   PubMedGoogle Scholar
• Hickey AJ. Pharmaceutical Inhalation Aerosol Technology (2nd Edition). Marcel Dekker, NY, USA (2004).
   Google Scholar
• Tobyn M, Staniforth JN, Morton D et al. Active and intelligent inhaler device development. Int. J. Pharm.277, 31–37 (2004).
   PubMedGoogle Scholar
• Middlebrook G. Immunological aspects of airborne infection: reactions to inhaled antigens. Bacterilog. Rev.25, 331–346 (1961).
   PubMedGoogle Scholar
• Jemski JV, Walker JS. Aerosol vaccination of mice with a live, temperature-sensitive recombinant influenza virus. Infect. Immun.13(3), 818–824 (1976).
   PubMedGoogle Scholar
• LiCalsi C, Christensen T, Bennett J et al. Dry powder inhalation as a potential delivery method for vaccines. Vaccine17, 1796–1803 (1999).
   PubMed Web of Science ®Google Scholar
• Hill M, Vaughan L, Dolovich M. Dose targeting for dry powder inhalers. In: Respiratory Drug Delivery. Dalby R, Bryon P, Farr S (Eds). Interpharm Press, Inc., IL, USA 197–208 (1996).
   Google Scholar
• Degen WGJ, Jansen T, Schijns VEJC. Vaccine adjuvant technology: from mechanistic concepts to practical applications. Expert Rev. Vaccines2(2), 327–335 (2003).
   PubMedGoogle Scholar
• Seong S-Y, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol.4(6), 469–478 (2004).
   PubMed Web of Science ®Google Scholar
• Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today8(20), 934–943 (2003).
   PubMed Web of Science ®Google Scholar
• Martin T, De Donato S, Minutello A et al. Safety and immunogenicity of biocine adjuvanted influenza vaccine in elderly patients. In: 7th European Congress of Clinical Microbiology and Infectious Diseases (Vienna). Excerpta Medica, Confer. Press. Austria, March 26–30, 1995.
   Google Scholar
• Kahn JO, Sinangil E, Baenziger J et al. Clinical and immunologic responses to human immunodeficiency virus (HIV) type I SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripep-tide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J. Infect. Dis.170, 1288–1291 (1994).
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine24, 5937–5949 (2006).
   PubMed Web of Science ®Google Scholar
• Couch RB. Nasal vaccination, Escherichia coli enterotoxin, and Bell’s palsy. N. Engl. J. Med.350(9), 860–861 (2004).
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P et al. Use of inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med.350(9), 896–903 (2004).
   PubMed Web of Science ®Google Scholar
• Lycke N. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM. Cell Microbiol.6, 23–32 (2004).
   PubMed Web of Science ®Google Scholar
• Peppoloni S, Ruggiero M, Contomi M et al. Mutants of the Escherichia coli heat-labile entertoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines2(2), 285–293 (2003).
   PubMedGoogle Scholar
• Nakaike S, Takeshita K, Shiono M et al. Studies of d-penicillamine on strain variability and lymph node cellularity in adjuvant arthritis. Agents Actions16, 514–520 (1985).
   PubMedGoogle Scholar
• Tebbey PW, Scheuer CA, Peek JA et al. Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H. Vaccine18, 2723–2734 (2000).
   PubMed Web of Science ®Google Scholar
• Cusi MG, Zurbriggen R, Correale P et al. Influenza virosome are an effective delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity. Vaccine20, 3436–3442 (2002).
   PubMed Web of Science ®Google Scholar
• Schmolka IR. A comparison of block copolymer surfactant gels. Am. Oil Chem. Soc.68, 206–209 (1997).
   Google Scholar
• Westerink MAJ, Smithson SL, Srivastava N et al. ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid. Vaccine20, 711–723 (2002).
   Web of Science ®Google Scholar
• Evora C, Soriano I, Rogers RA et al. Relating the phagocytosis of microparticules by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J. Control. Release51, 143–152 (1998).
   PubMed Web of Science ®Google Scholar
• Densmore CL. Polyethylenimine-based gene therapy by inhalation. Expert Opin. Biol. Ther.3(7), 1083–1092 (2003).
   PubMedGoogle Scholar
• Raychaudhuri A, Rock KL. Fully mobilizing host defense: building better vaccines. Nat. Biotechnol.16, 1025–1031 (1998).
   PubMed Web of Science ®Google Scholar
• Gilbert BE, Wyde PR, Wilson SZ et al. Aerosol and intraperitoneal administration of ribavarin and ribavarin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A/WDN virus. Antimicrob. Agents Chemother.35, 1448–1453 (1991).
   PubMed Web of Science ®Google Scholar
• Parthasarathy R, Gilbert B, Mehta K. Aerosol delivery of liposomal all-trans retinoic acid to the lungs. Cancer Chemother. Pharmacol.43, 277–283 (1999).
   PubMed Web of Science ®Google Scholar
• Lu D, Hickey AJ. Liposomal dry powders as aerosols for pulmonary delivery of proteins. AAPS Pharm. Sci. Tech.6(4), E641–E648 (2005).
   PubMed Web of Science ®Google Scholar
• Niven RW, Speer M, Schreier H. Nebulization of liposomes. I. Effects of lipid compositions. Pharm. Res.9, 515–520 (1992).
   PubMed Web of Science ®Google Scholar
• Schreier H, Mobley WC, Concessio N et al. Formulation and in vitro performance of liposome powder aerosols. STP Pharma. Sci.4, 38–44 (1994).
   Google Scholar
• Skalko-Basnet N, Pavelic Z, Becirevic-Lacan M. Liposomes containing drug and cyclodextrin prepared by the one-step spray-drying method. Drug Dev. Ind. Pharm.26, 1279–1284 (2000).
   PubMed Web of Science ®Google Scholar
• de Haan A, Groen G, Prop J et al. Mucosal immunoadjuvant activity of liposomes: role of alveolar macrophages. Immunology89(4), 488–493 (1996).
   PubMed Web of Science ®Google Scholar
• Griffiths GD. Liposomally-encapsulated ricin toxoid vaccine delivered intratracheally elicits a good immune response and protects against a lethal pulmonary dose of ricin toxin. Vaccine15, 1933–1939 (1997).
   PubMed Web of Science ®Google Scholar
• Griffiths GD, Philips GJ, Bailey SC. Comparison of the quality of protection elicited by toxoid and peptide liposomal vaccine formulations against ricin as assessed by markers of imflammation. Vaccine17, 2563–2568 (1999).
   Google Scholar
• Burgener D, Huckriede A, Wilschut J. Virosomes as an antigen delivery system. J. Liposome Res.10, 329–338 (2000).
   Google Scholar
• Lowell GH, Kaminski RW, Grate S et al. Intransal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice. Infect. Immun.64(5), 1706–1713 (1996).
   PubMed Web of Science ®Google Scholar
• Lowell GH, Colleton C, Frost D et al. Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines. Infect. Immun.64(11), 4686–4693 (1996).
   PubMed Web of Science ®Google Scholar
• Bot A, Smith DJ, Bot S et al. Receptor-mediated targeting of spray-dried lipid particles coformulated with immunoglobin and loaded with a prototype vaccine. Pharm. Res.18(7), 971–979 (2001).
   PubMed Web of Science ®Google Scholar
• Saraf S, Mishra D, Asthana A et al. Lipid microparticles for mucosal immunization against hepeatitis B. Vaccine24(1), 45–56 (2006).
   PubMed Web of Science ®Google Scholar
• Flick-Smith HC, Eyles JE, Hebdon R et al. Mucosal or parenteral adminstration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect. Immun.70(4), 2022–2028 (2002).
   PubMed Web of Science ®Google Scholar
• Eyles JE, Sharp GJE, Williamson ED et al. Intranasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine16(7), 698–707 (1998).
   PubMed Web of Science ®Google Scholar
• Eyles JE, Williamson ED, Spiers ID et al. Protection studies following bronchopulmonary and intramuscular imunization with Yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy. Vaccine18, 3266–3271 (2000).
   PubMed Web of Science ®Google Scholar
• Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol.27(12), 573–579 (2006).
   PubMed Web of Science ®Google Scholar
• Avrameas A, McIlroy D, Hosmalin A et al. Expression of a mannose/fucose membrane lectin on human dendritic cells. Eur. J. Immunol.26, 394–400 (1996).
   PubMed Web of Science ®Google Scholar
• Copland MJ, Baird MA, Radesa T et al. Liposomal delivery of antigen to human dendritic cells. Vaccine21, 883–890 (2003).
   PubMed Web of Science ®Google Scholar
• Bivas-Benita M, Zwier R, Junginger HE et al. Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur. J. Pharm. Biopharm.61, 214–218 (2005).
   PubMed Web of Science ®Google Scholar
• Dailey LA, Kleemann E, Wittmar M et al. Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA. Pharm. Res.20, 2011–2020 (2003).
   PubMed Web of Science ®Google Scholar
• Hadinoto K, Phanapavudhikul P, Kewu Z, Tan RB. Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids. Int. J. Pharm.333(1–2), 187–198 (2006).
   PubMedGoogle Scholar
• Sham JO, Zhang Y, Finlay WH et al. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int. J. Pharm.269, 457–467 (2004).
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. Macrophages phagocytosis of biodegradable microspheres composed of l-lactic acid/glycolic acid homo- and copolymers. J. Biomed. Mater. Res.22, 837–858 (1988).
   PubMed Web of Science ®Google Scholar
• Lemiale F, Kong WP, Akyurek LM et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J. Virol.77, 10078–10087 (2003).
   PubMed Web of Science ®Google Scholar
• Wang J, Thorson L, Stokes RW et al. Single mucosal, but not perenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol.173, 6357–6365 (2004).
   PubMed Web of Science ®Google Scholar
• Liu M, Acres B, Balloul JM et al. Gene-based vaccines and immunotherapeutics. Proc. Natl Acad. Sci. USA101(Suppl. 2), 14567–14571 (2004).
   PubMed Web of Science ®Google Scholar
• Derrick SC, Yang AL, Morris SL. Vaccination with a Sindbis virus-based DNA vaccine expressing antigen 85B induces protective immunity against Mycobacterium tuberculosis. Infect. Immun.73(11), 7727–7735 (2005).
   PubMed Web of Science ®Google Scholar
• Singh M, Ugozzoli M, Briones M et al. The effect of CTAB concentration in cationic PLG microparticles on DNA adsorption and in vivo performance. Pharm. Res.20, 247–251 (2003).
   PubMed Web of Science ®Google Scholar
• Densmore CL, Orson FM, Xu B et al. Aerosol delivery of robust polyethyleneimine–DNA complexes for gene therapy and genetic immunization. Mol. Ther.1, 180–188 (2000).
   PubMed Web of Science ®Google Scholar
• Regnstrom K, Ragnarsson EG, Koping-Hoggard M et al. PEI-a potent, but not harmless, mucosal immunostimulator of mixed T-helper cell response and FasL-mediated cell death in mice. Gene Ther.10, 1575–1583 (2003).
   PubMed Web of Science ®Google Scholar
• Harcourt JL, Anderson LJ, Sullender W, Tripp RA. Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggragated albumin particles. Vaccine22, 2248–2260 (2004).
   PubMed Web of Science ®Google Scholar
• Steckel H, Bolzen N. Alternative sugars as portential carriers for dry powder inhalations. Int. J. Pharm.270, 297–306 (2004).
   PubMed Web of Science ®Google Scholar
• Byron PR. Determinants of drug and polypeptide bio-availability from aerosols delivered to the lungs. Adv. Drug Deliv. Rev.5, 107–132 (1990).
   Google Scholar
• Chan HK, Clark A, Gondal MM et al. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm. Res.14, 431–437 (1997).
   PubMed Web of Science ®Google Scholar
• Lucas P, Anderson K, Staniforth JN. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers. Pharm. Res.15, 562–569 (1998).
   PubMed Web of Science ®Google Scholar
• Shah SP, Misra A. Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance. AAPS Pharm. Sci. Tech.5(4), E65 (2004).
   PubMed Web of Science ®Google Scholar
• Maa YF, Nguyen PA, Sweny T et al. Protein inhalation powders: spray drying vs spray freeze-drying. Pharm. Res.16, 249–254 (1999).
   PubMed Web of Science ®Google Scholar
• Kuo MC, Tep V, Yang B et al. Effect of hygroscopic growth inhibitors on dry powder aerosol performance and bioavailability. American Association of Pharmaceutical Scientists Meeting. Ontario, Canada, November 10–14, 2002.
   Google Scholar
• Edwards DA, Hanes J, Caponetti G et al. Large porous particles for pulmonary drug delivery. Science276, 1868–1871 (1997).
   PubMed Web of Science ®Google Scholar
• Mohamed F, van der Walle CF. PLGA microcapsules with novel dimpled surfaces for pulmonary delivery of DNA. Int. J. Pharm.311, 97–107 (2006).
   PubMed Web of Science ®Google Scholar
• Rottem M, Shoenfeld Y. Vaccination and allergy. Curr. Opin. Otolaryngol. Head Neck Surg.12(3), 223–231 (2004).
   PubMedGoogle Scholar
• Suman JD, Laube BL, Dalby RN. Comparison of nasal deposition and clearance of aerosol generated by nebulizer and an aqueous spray pump. Pharm. Res.16(10), 1648–1652 (1999).
   PubMed Web of Science ®Google Scholar
• Alpar HO, Bramwell VW. Current status of DNA vaccines and their route of adminstration. Crit. Rev. Ther. Drug Carr. Syst.19, 307–383 (2002).
   PubMed Web of Science ®Google Scholar
• Mikszta JA, Sullivan VJ, Dean C et al. Protective immunization against inhalational antrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis.191, 278–288 (2005).
   PubMed Web of Science ®Google Scholar
• Hu KF, Merza EM, Akerblom L et al. The immunostimulating complex is an efficient mucosal delivery system for respiratory syncytial virus envelope antigens inducing high local and systemic antibody responses. Clin. Exp. Immunol.113, 235–243 (1998).
   PubMed Web of Science ®Google Scholar
• Borsutzky S, Fiorelli V, Ebensen T et al. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur. J. Immunol.33, 1548–1556 (2003).
   PubMed Web of Science ®Google Scholar
• Wimer-Mackin S, Hinchcliffe M, Petrie CR et al. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Vaccine24(18), 3953–3963 (2006).
   PubMed Web of Science ®Google Scholar
• Falero-Diaz G, Challacombe S, Bamerjee D et al. Intranasal vaccination of mice against infection with Mycoacterium tuberculosis. Vaccine18, 3223–3229 (2000).
   PubMed Web of Science ®Google Scholar
• Boyaka PN, Tafaro A, Fischer R et al. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell response following nasal immunization with protective antigen. J. Immunol.170, 5636–5643 (2003).
   PubMed Web of Science ®Google Scholar
• Tumpey TM, Renshaw M, Clements JD et al. Mucosal delivery of inactivated influenza vaccine induces B cell dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virology75(11), 5141–5150 (2001).
   PubMed Web of Science ®Google Scholar
• de Haan A, Tomee JFC, Huchshorn JP et al. Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measlese virus administered intranasally to mice. Vaccine13, 1320–1324 (1995).
   PubMed Web of Science ®Google Scholar
• de Haan A, Geerigs HJ, Huchshorn JP et al. Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine13, 1320–1324 (1995).
   PubMed Web of Science ®Google Scholar
• Lowell GH, Kaminski RW, Grate S et al. Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice. Infect. Immun.64(5), 1706–1713 (1996).
   PubMed Web of Science ®Google Scholar
• Carpenter ZC, Williams ED, Eyles JE. Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu. J. Control Release104, 67–77 (2005).
   PubMed Web of Science ®Google Scholar
• Greenway TE, Eldridge JH, Ludwig G et al. Induction of protective immune responses against venezuelan equine encephalitis (VEE) virus aerosol challenge with microsencapsulated VEE virus vaccine. Vaccine15(13), 1314–1323 (1998).
   Google Scholar
• Cahill ES, O’Hagan DT, Illum L et al. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles Vaccine13(5), 455–462 (1995).
   PubMed Web of Science ®Google Scholar